You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / CE

New Horizons in Treating Hypertrophic Cardiomyopathy: Practice Changing Molecules and Data

  • Authors: Theodore Abraham, MD, FACC, FASE; Sara Saberi, MD, MS; Anjali Owens, MD
  • CME / CE Released: 11/3/2022
  • Valid for credit through: 11/3/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.25 AMA PRA Category 1 Credit(s)™

    Nurses - 1.25 ANCC Contact Hour(s) (1.25 contact hours are in the area of pharmacology)

    Pharmacists - 1.25 Knowledge-based ACPE (0.125 CEUs)

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for cardiologists, primary care physicians, surgeons, nurses/nurse practitioners, and pharmacists.

The goal of this activity is for learners to be better able to improve knowledge of emerging cardiac myosin inhibitor therapy, the latest clinical data for cardiac myosin inhibitor therapies that target the underlying sarcomere dysfunction in HCM, and how to integrate this new evidence into clinical practice for appropriate patients.

Upon completion of this activity, participants will:

  • Identify sarcomere dysfunction as a therapeutic target in HCM
  • Analyze new data for the use of sarcomere-directed therapies to treat HCM
  • Differentiate emerging cardiac myosin inhibitors for the treatment of HCM
  • Identify patients who may benefit from novel cardiac myosin inhibition treatment strategies


Disclosures

Disclosure

The Heart Failure Society of America (HFSA) is committed to fair and balanced educational content that is independent of industry influence. Participants are ensured objectivity and scientific rigor in all continuing education (CE) activities, free from the appearance of or actual conflicts of interest (COI).

It is the policy of the Heart Failure Society of America (HFSA) that all individuals who serve on a committee or in any position to influence the content of a certified CE activity must disclose all financial relationships with any ineligible companies that have occurred over the past 24 months.

An ineligible company is defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; all financial relationships, regardless of the amount, with ineligible companies must be disclosed.

All potential conflicts of interests have been resolved in accordance with the Joint Accreditation Standards for Integrity and Independence in Accredited Continuing Education.


Moderator

  • Theodore Abraham, MD, FACC, FASE

    Cardiologist
    Meyer Friedman Distinguished Professor of Medicine
    Director, UCSF Adult Cardiac Echocardiography Laboratory
    University of California San Francisco
    San Francisco, California

    Disclosures

    Theodore P. Abraham, MD, has no relevant financial relationships.

Faculty

  • Sara Saberi, MD, MS

    Assistant Professor
    Inherited Cardiomyopathy Program
    Frankel Cardiovascular Center
    University of Michigan Hospital Michigan Medicine
    Ann Arbor, Michigan

    Disclosures

    Sara Saberi, MD, MS, has the following relevant financial relationships:
    Consultant or advisor for: Bristol Myers Squibb; Cytokinetics
    Research funding from: Bristol Myers Squibb; Cytokinetics; Novartis
    Contracted researcher for: Bristol Myers Squibb; Cytokinetics; Novartis

  • Anjali Owens, MD

    Associate Professor of Medicine
    Hospital of the University of Pennsylvania
    Director, Penn Familial Cardiomyopathy Program
    Director, Penn Center for Inherited Cardiovascular Disease
    University of Pennsylvania
    Philadelphia, Pennsylvania

    Disclosures

    Anjali T. Owens, MD, has the following relevant financial relationships:
    Consultant or advisor for: Bristol Myers Squibb/MyoKardia; Cytokinetics; Pfizer
    Research funding from: Bristol Myers Squibb/MyoKardia; Cytokinetics; Pfizer

Editor

  • Joy P. Marko, MS, APN-C, CCMEP

    Senior Medical Education Director, Medscape, LLC

    Disclosures

    Joy P. Marko, MS, APN-C, CCMEP, has no relevant financial relationships.

  • Frederick Stange, DO

    Scientific Content Manager, Medscape, LLC

    Disclosures

    Frederick Stange, DO, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Lisa Simani, APRN, MS, ACNP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

HFSA Review Committee Disclosures

  • Jennifer Cook

    Disclosures

    Jennifer Cook has the following relevant financial relationships:
    Formerly employed by an ineligible company: Itmar Medical

  • Robert Didomenico

    Disclosures

    Robert Didomenico has the following relevant financial relationships:
    Consultant or advisor for: ABIOMED; PhaseBio
    Research funding from: CSL Behring

  • Daniel Garry

    Disclosures

    Daniel Garry has the following relevant financial relationships:
    Other: Board Member for NorthStar Genomics

  • David Lanfear

    Disclosures

    David Lanfear has the following relevant financial relationships:
    Consultant or advisor for: Abbott Laboratories; Amgen; AstraZeneca; Cytokinetics; Illumina; Janssen; Martin Pharmaceuticals
    Research funding from: Lilly; SomaLogic

  • Cheryl Westlake

    Disclosures

    Cheryl Westlake has no relevant financial relationships.


Accreditation Statements


Developed through a collaboration between the “Accredited Provider: Heart Failure Society of America” and Medscape Education.



In support of improving patient care, the Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • The Heart Failure Society of America designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity includes participation in the evaluation component and post-test.

    Contact This Provider

    For Nurses

  • This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America.  This activity is approved for a maximum 1.25 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity. 

    Contact This Provider

    For Pharmacists

  • The Heart Failure Society of America is an accredited provider of continuing pharmacy education (CPE). This event is accredited for up to 1.25 contact hours of knowledge-based CPE.  ACPE Universal Activity Numbers (UAN): JA4008267-0000-22-017-H04-P. 

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / CE

New Horizons in Treating Hypertrophic Cardiomyopathy: Practice Changing Molecules and Data

Authors: Theodore Abraham, MD, FACC, FASE; Sara Saberi, MD, MS; Anjali Owens, MDFaculty and Disclosures

CME / CE Released: 11/3/2022

Valid for credit through: 11/3/2023

processing....

Learning Feedback Questions

Please answer these questions to complement your learning experience.